Medicare caps seniors drug expenses: What you need to know
Medicare recipients who take expensive prescriptions will get a break this year with a $2,000 cap on drug costs.
Acelyrin falls after updating mid-stage trial data for eye disease drug
Acelyrin (SLRN) stock dropped 32% after Phase 2 trial results for lonigutamab its experimental treatment for thyroid eye disease. Read more here.
Pharmaceutical Technology4d
Alphaf-001 by Alpha Fusion for Follicular Thyroid Cancer: Likelihood of Approval
Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.
I exercised and ate well but still developed a terrifying ‘life-sentence’ disease – let my ordeal be a warning
THREE years ago, my life changed in ways I could never have imagined.  I was 23, living what I thought was a healthy life, when seemingly out of nowhere, my body began to betray me.  I ...